PARP Inhibitor Market: Growing Demand for Targeted Therapies to Drive Market Growth
![]() |
PARP Inhibitor Market |
Market
Overview:
PARP
inhibitors are a type of targeted therapy that work by inhibiting the activity
of the enzyme poly ADP-ribose polymerase (PARP), which plays a key role in DNA
repair. These inhibitors have shown promising results in the treatment of
various types of cancer, especially in patients with BRCA1 and BRCA2 gene
mutations. The advantages of PARP inhibitors include increased response rates,
improved progression-free survival, and reduced side effects compared to
traditional chemotherapy.
Market Key Trends:
One key trend in the PARP Inhibitor Market is the increasing number of
collaborations and partnerships between pharmaceutical companies. These
collaborations aim to leverage the strengths and expertise of different
companies to accelerate the development and commercialization of PARP
inhibitors. For example, AstraZeneca Plc. and Merck KGaA entered into a
strategic collaboration to co-develop and commercialize a PARP inhibitor for
the treatment of various cancers. Such collaborations help in expanding the
product pipeline and reaching a wider patient population, driving the market
growth of PARP inhibitors.
Porter’s
Analysis:
Threat of New Entrants: The threat of new entrants in the PARP
Inhibitor Market Share is relatively low. The market is highly
specialized and requires significant investment in research and development to
develop effective PARP inhibitors. Additionally, there are several established
players with strong market presence and intellectual property rights, making it
difficult for new entrants to compete.
Bargaining Power of Buyers: The bargaining power of buyers in the PARP
Inhibitor market is moderate. Buyers, such as healthcare providers and
patients, have a range of options when it comes to choosing PARP inhibitors,
which gives them some leverage in negotiations. However, the high demand for
these drugs and limited alternatives limits their bargaining power to some
extent.
Bargaining Power of Suppliers: The bargaining power of suppliers in the PARP
Inhibitor market is low. The market is dominated by pharmaceutical companies
that have developed their own PARP inhibitors or have licensing agreements with
suppliers. These companies have strong negotiating power and can dictate terms
to suppliers, resulting in lower bargaining power for suppliers.
Threat of New Substitutes: The threat of new substitutes in the PARP Inhibitor
market is low. PARP inhibitors are a specialized class of drugs used for
targeted cancer therapy, and there are limited alternatives that offer similar
efficacy. The high cost of research and development in this field also acts as
a barrier to the development of new substitutes.
Competitive Rivalry: The competitive rivalry in the PARP Inhibitor market is
high. There are several key players operating in the market, including
AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline Plc., Pfizer, Inc.,
Clovis Oncology Inc., AbbVie Inc., Bristol Myers Squibb, Merck KGaA, Genentech,
Inc., Artios Pharma, Repare Therapeutics Inc., Sierra Oncology, Inc.,
Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., Ltd., and Jiangsu Hengrui
Medicine Co., Ltd. These companies compete on factors such as drug efficacy,
safety profile, pricing, and market reach.
Key Takeaways:
The global PARP Inhibitor market is expected to witness high growth, exhibiting
a CAGR of 32.4% over the forecast
period. This growth can be attributed to the increasing prevalence of cancer,
especially ovarian and breast cancer, which are the primary indications for
PARP inhibitors. Additionally, advancements in personalized medicine and the
growing adoption of targeted therapies contribute to the market growth.
Regionally, North America is the fastest-growing and dominating region in the
PARP Inhibitor market. The region has a well-developed healthcare
infrastructure, high adoption of advanced therapies, and a large patient pool.
Moreover, the presence of key market players and ongoing research and
development activities in this region further contribute to its dominance.
Key players operating in the PARP Inhibitor market include AstraZeneca Plc.,
Johnson & Johnson, GlaxoSmithKline Plc., Pfizer, Inc., Clovis Oncology
Inc., AbbVie Inc., Bristol Myers Squibb, Merck KGaA, Genentech, Inc., Artios
Pharma, Repare Therapeutics Inc., Sierra Oncology, Inc., Karyopharm
Therapeutics Inc., Ono Pharmaceutical Co., Ltd., and Jiangsu Hengrui Medicine
Co., Ltd. These companies hold significant market shares and constantly strive
to develop new and improved PARP inhibitors to maintain their competitive edge.
Read More:
https://www.dailyprbulletin.com/parp-inhibitor-market-demand-growth-and-share/
Comments
Post a Comment